Allurion Technologies Inc...
(ALUR)
undefined
undefined%
At close: undefined
0.33
-1.01%
After-hours Dec 13, 2024, 07:37 PM EST
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
The company is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
| Country | United States |
| IPO Date | Mar 29, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 501 |
| CEO | Dr. Shantanu K. Gaur M.D. |
Contact Details
Address: 11 Huron Drive Natick, Massachusetts United States | |
| Website | https://www.allurion.com |
Stock Details
| Ticker Symbol | ALUR |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001964979 |
| CUSIP Number | 02008G102 |
| ISIN Number | US02008G1022 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President, Principal Financial & Accounting Officer and Director |
| Brendan Michael Gibbons J.D. | Chief Legal Officer & Corporate Secretary |
| Ojas A. Buch | Chief Operating Officer |
| Dr. Samuel G. Levy | Co-Founder |
| Joyce Johnson | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Matt Wright | Vice President of People |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | S-3 | Filing |
| Dec 10, 2024 | S-1 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | 424B3 | Filing |
| Nov 14, 2024 | 424B3 | Filing |
| Nov 14, 2024 | 424B3 | Filing |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |